Skip to content
DataLookout
Menu

NCT07883070

Study of Anxiety and Depression in Patients With Hematologic Malignancies

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Study title expanded, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Treatment Failure Within 24 Months
Timeframe: From treatment initiation through 24 months.

Secondary (4)

Progression-Free Survival (PFS)
Overall Survival (OS)
Overall Response Rate (ORR)
Complete Response Rate (CR Rate)

Arms and interventions

Anxiety and/or Depression Group

Patients with newly diagnosed lymphoma or multiple myeloma who have a baseline Hospital Anxiety and Depression Scale-Anxiety (HADS-A) score of 8 or higher and/or a Hospital Anxiety and Depression Scale-Depression (HADS-D) score of 8 or higher. All patients receive standard anticancer treatment according to routine clinical practice.

No Anxiety or Depression Group

Patients with newly diagnosed lymphoma or multiple myeloma who have baseline HADS-A and HADS-D scores both below 8. All patients receive standard anticancer treatment according to routine clinical practice.

Other: Baseline Anxiety and/or Depression

Sites

1 site in 1 country

  • the First Affilaited Hospital of Xiamen UniversityXiamen, Fujian, China